Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine
Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational combination vaccine against influenza and COVID-19.
The vaccines are “designed to deliver value to individuals, providers and healthcare systems through higher compliance, easier administration and greater convenience,” according to the company’s press release.
The trial compared mRNA-1083 to the Fluarix vaccine in patients aged 50-64 and Fluzone HD in patients 65-79; in both age groups it was compared to the Spikevax booster.
The vaccine candidate achieved hemagglutination inhibition antibody titers similar to or greater than both licensed quadrivalent influenza vaccines as well as achieving SARS-CoV-2 neutralising antibody titers similar to the Spikevax bivalent booster in the phase 1/2 study.
Stéphane Bancel, Moderna’s chief executive officer, commented: “With today’s positive results from our combination vaccine against flu and COVID-19, we continue to expand our phase 3 pipeline. Flu and COVID-19 represent a significant seasonal burden for individuals, providers, healthcare systems and economies. Combination vaccines offer an important opportunity to improve consumer and provider experience, increase compliance with public health recommendations, and deliver value for healthcare systems. We are excited to move combination respiratory vaccines into phase 3 development and look forward to partnering with public health officials to address the significant seasonal threat posed to people by these viruses.”
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …
GSK has announced positive results from a planned interim efficacy analysis of the phase 3 …
Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results …